By creator to www.biospectrumasia.com
42 roxadustat abstracts will probably be introduced on the American Society of Nephrology Kidney Week 2020 Reimagined congress
Japan-based Astellas Pharma Inc. (Astellas) has introduced that in collaboration with FibroGen and AstraZeneca, 42 roxadustat abstracts will probably be introduced on the American Society of Nephrology (ASN) Kidney Week 2020 Reimagined congress being held from Oct 22- 25.
Six abstracts (one oral presentation and 5 ePosters) sponsored by Astellas concentrate on using roxadustat as a remedy in grownup sufferers with anemia of persistent kidney illness (CKD). These abstracts embrace shows of the Section three DOLOMITES examine and a Japanese Section three CL-0310 examine, with each research evaluating roxadustat versus darbepoetin alfa as a remedy for sufferers with anemia of CKD, not on dialysis. Different shows embrace security information from two Japanese Section three research assessing the ophthalmological results of roxadustat remedy in sufferers with anemia of CKD on dialysis and never on dialysis, and a examine of sufferers’ remedy preferences for anemia of CKD.